Literature DB >> 29436735

Relationship between cerebrospinal fluid biomarkers and structural brain network properties in Parkinson's disease.

Nooshin Abbasi1,2, Bahram Mohajer1,2, Sima Abbasi3, Payam Hasanabadi3, Amirhussein Abdolalizadeh1,2, Reza Rajimehr4.   

Abstract

BACKGROUND: Pathological accumulation of α-synuclein, amyloid-β42 , and tau proteins in the brain is considered critical for development of various neurodegenerative diseases.
OBJECTIVES: We investigated the association between CSF levels of these biomarkers, brain structural connectivity, and the UPDRS in PD.
METHODS: Diffusion tensor images and CSF biomarkers (α-synuclein, amyloid-β42 , total tau, and phosphorylated tau181) from 132 drug-naïve, nondemented PD patients and 61 healthy controls were obtained from the Parkinson's Progression Markers Initiative database. After network reconstruction of structural connectivity patterns, global interconnectivity measures (including global efficiency, clustering coefficient, and characteristic path length) and local efficiency were calculated. Network properties and CSF biomarkers were compared between PD patients and healthy controls. The association of CSF biomarkers with network properties and UPDRS-III score was investigated.
RESULTS: Global measures (but not local efficiency) and CSF α-synuclein were significantly lower in PD patients. Global efficiency and clustering coefficient correlated positively with α-synuclein, Aβ42 , and total tau CSF levels. Furthermore, these CSF biomarkers showed no significant association with the UPDRS-III score.
CONCLUSIONS: This study examined the association of CSF biomarkers that reflect the brain pathology, with structural brain connectivity and UPDRS-III in PD. Our results revealed an association between the abnormal aggregation of α-synuclein, Aβ42 , and tau proteins and structural connectivity disruption in PD patients. In summary, a combination of structural imaging and measurement of CSF biomarkers provide a better understanding of the pathogenesis of PD.
© 2018 International Parkinson and Movement Disorder Society. © 2018 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  CSF biomarkers; DTI; Parkinson's disease; UPDRS; structural networks

Mesh:

Substances:

Year:  2018        PMID: 29436735     DOI: 10.1002/mds.27284

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

1.  Iron-related nigral degeneration influences functional topology mediated by striatal dysfunction in Parkinson's disease.

Authors:  Xiaojun Guan; Yuyao Zhang; Hongjiang Wei; Tao Guo; Qiaoling Zeng; Cheng Zhou; Jiaqiu Wang; Ting Gao; Min Xuan; Quanquan Gu; Xiaojun Xu; Peiyu Huang; Jiali Pu; Baorong Zhang; Chunlei Liu; Minming Zhang
Journal:  Neurobiol Aging       Date:  2018-11-22       Impact factor: 4.673

Review 2.  Global Alterations of Whole Brain Structural Connectome in Parkinson's Disease: A Meta-analysis.

Authors:  Chao Zuo; Xueling Suo; Huan Lan; Nanfang Pan; Song Wang; Graham J Kemp; Qiyong Gong
Journal:  Neuropsychol Rev       Date:  2022-09-20       Impact factor: 6.940

3.  REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.

Authors:  Fardin Nabizadeh; Kasra Pirahesh; Parya Valizadeh
Journal:  J Neurol       Date:  2022-04-15       Impact factor: 6.682

4.  Robust Ensemble Classification Methodology for I123-Ioflupane SPECT Images and Multiple Heterogeneous Biomarkers in the Diagnosis of Parkinson's Disease.

Authors:  Diego Castillo-Barnes; Javier Ramírez; Fermín Segovia; Francisco J Martínez-Murcia; Diego Salas-Gonzalez; Juan M Górriz
Journal:  Front Neuroinform       Date:  2018-08-14       Impact factor: 4.081

5.  Disrupted morphological grey matter networks in early-stage Parkinson's disease.

Authors:  Xueling Suo; Du Lei; Nannan Li; Wenbin Li; Graham J Kemp; John A Sweeney; Rong Peng; Qiyong Gong
Journal:  Brain Struct Funct       Date:  2021-04-07       Impact factor: 3.270

6.  Tau and Amyloid-β Peptides in Serum of Patients With Parkinson's Disease: Correlations With CSF Levels and Clinical Parameters.

Authors:  Tommaso Schirinzi; Henri Zenuni; Piergiorgio Grillo; Roberta Bovenzi; Gisella Guerrera; Francesca Gargano; Massimo Pieri; Sergio Bernardini; Nicola Biagio Mercuri; Luca Battistini; Giulia Maria Sancesario
Journal:  Front Neurol       Date:  2022-02-25       Impact factor: 4.003

7.  Disrupted Brain Structural Network Connection in de novo Parkinson's Disease With Rapid Eye Movement Sleep Behavior Disorder.

Authors:  Amei Chen; Yuting Li; Zhaoxiu Wang; Junxiang Huang; Xiuhang Ruan; Xiaofang Cheng; Xiaofei Huang; Dan Liang; Dandan Chen; Xinhua Wei
Journal:  Front Hum Neurosci       Date:  2022-07-19       Impact factor: 3.473

8.  Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.

Authors:  Farzaneh Ghazi Sherbaf; Bahram Mohajer; Amir Ashraf-Ganjouei; Mahtab Mojtahed Zadeh; Ali Javinani; Hossein Sanjari Moghaddam; Mehdi Shirin Shandiz; Mohammad Hadi Aarabi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-02       Impact factor: 5.555

Review 9.  Parkinson's Disease Subtyping Using Clinical Features and Biomarkers: Literature Review and Preliminary Study of Subtype Clustering.

Authors:  Seung Hyun Lee; Sang-Min Park; Sang Seok Yeo; Ojin Kwon; Mi-Kyung Lee; Horyong Yoo; Eun Kyoung Ahn; Jae Young Jang; Jung-Hee Jang
Journal:  Diagnostics (Basel)       Date:  2022-01-04

10.  Effects of head trauma and sport participation in young-onset Parkinson's disease.

Authors:  Tommaso Schirinzi; Piergiorgio Grillo; Giulia Di Lazzaro; Henri Zenuni; Chiara Salimei; Kristen Dams-O'Connor; Giulia Maria Sancesario; Nicola Biagio Mercuri; Antonio Pisani
Journal:  J Neural Transm (Vienna)       Date:  2021-07-14       Impact factor: 3.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.